The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INBX | +429.29% | N/A | N/A | +480% |
| S&P | +12.93% | +85.68% | +13.18% | +29% |
Inhibrx Biosciences, Inc. operates as an American clinical-stage biotechnology company for biologic therapeutic candidates. The private company is based in DE.
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.58M | 23.4% |
| Gross Margin | 49.08% | 424.1% |
| Market Cap | $487.87M | 115.2% |
| Market Cap / Employee | $3.03M | 0.0% |
| Employees | 161 | 0.0% |
| Net Income | -$35.26M | 19.6% |
| EBITDA | -$33.23M | 27.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $153.09M | -22.0% |
| Accounts Receivable | $0.11M | -90.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $104.66M | 0.0% |
| Short Term Debt | $2.25M | 22.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -77.54% | 0.0% |
| Return On Invested Capital | 351.55% | 426.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$33.83M | -10.8% |
| Operating Free Cash Flow | -$33.82M | -11.7% |
| Metric | Q4 2024 | Q1 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 0.13 | 0.12 | - | ||
| Price to Book | 1.25 | 1.52 | 2.19 | 7.11 | 588.16% |
| Price to Sales | 1114.64 | 1081.99 | 157.66 | 372.36 | - |
| Price to Tangible Book Value | 1.25 | 1.52 | 2.19 | 7.11 | 588.16% |
| Enterprise Value to EBITDA | -1.59 | -2.52 | -5.27 | -14.30 | 1944.47% |
| Return on Equity | 3250.6% | -113.7% | -144.1% | - | |
| Total Debt | $8.05M | $106.53M | $106.79M | $106.91M | 5725.89% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
